Scarica l'app Stockscreener
34.07
1.02%
-0.35
Pre-mercato:
34.17
0.10
+0.29%
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - TradingView
(COLL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story - simplywall.st
Collegium Pharmaceutical stock (US19459E1029): insider trade draws attention as Wall Street sees ups - AD HOC NEWS
Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952 - Stock Titan
COLL Stock Price, Quote & Chart | COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) - ChartMill
Collegium Pharma Leans on ADHD to Drive Growth - TipRanks
Collegium pharmaceutical director sells $142k in shares By Investing.com - Investing.com South Africa
Collegium pharmaceutical director sells $142k in shares - Investing.com India
Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL) - Stock Titan
Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL) - Stock Titan
Collegium (COLL) director sells shares, exercises options and receives RSU grant - Stock Titan
Director at Collegium (COLL) awarded 17,482 restricted stock units - Stock Titan
Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award - Stock Titan
Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant - Stock Titan
COLL (NASDAQ) Form 144 shows 4,127-share sale and 30-share resale notice - Stock Titan
Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3 - Stock Titan
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Have Collegium Pharmaceutical Insiders Been Selling Stock? - simplywall.st
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Collegium Pharmaceutical stock (US19459E1029): opioid-pain specialist in focus after Q1 2026 earning - AD HOC NEWS
Collegium Shareholders Back Board, Pay and Auditor Choices - TipRanks
Collegium (NASDAQ: COLL) shareholders back board, pay and auditor at 2026 meeting - Stock Titan
Collegium Pharmaceutical (COLL) director sells 4,500 shares in market trade - Stock Titan
Janus Henderson (COLL) reports 1.83M-share, 5.8% holding in PHARMACEUTICAL, INC. - Stock Titan
[SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment Disclosure - Stock Titan
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality - 富途牛牛
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating - Moomoo
Renaissance files 4.53% holding in PHARMACEUTICAL, INC (COLL) - Stock Titan
Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Statutory Profit Doesn't Reflect How Good Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are - simplywall.st
Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics stocks trade down, what you need to know - MSN
Collegium (NASDAQ: COLL) director exercises options, sells 8,700 shares at $37 - Stock Titan
Earnings call transcript: Collegium Pharmaceutical Q1 2026 beats estimates By Investing.com - Investing.com Canada
Collegium Pharmaceutical (NASDAQ: COLL) group filings show shared 4.7% positions - Stock Titan
Collegium Pharmaceutical Completes Azstarys Acquisition, Raises 2026 Net Product Revenue Guidance - Moomoo
Collegium Pharmaceutical Acquires AZSTARYS®, Expanding ADHD Portfolio and Raising 2026 Financial Guidance - Minichart
TradingKey - TradingKey
Collegium Pharmaceutical Completes $650 Million AZSTARYS Acquisition From Corium - citybiz
Collegium Pharmaceutical Completes AZSTARYS ADHD Business Acquisition - TipRanks
Collegium completes acquisition of Azstarys® from Corium Therapeutics - marketscreener.com
AZSTARYS deal lifts Collegium (NASDAQ: COLL) 2026 revenue and EBITDA outlook - Stock Titan
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics - GlobeNewswire
A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed - Sahm
Responsive Playbooks and the COLL Inflection - Stock Traders Daily
ADHD drug AZSTARYS sells for $650M, with patents lasting to 2037 - Stock Titan
Collegium Pharmaceutical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:COLL) 2026-05-11 - Seeking Alpha
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results - Yahoo Finance
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off - The Globe and Mail
Collegium (COLL) Q1 2026 Earnings Transcript - AOL.com
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Regeneron (REGN) and Collegium Pharmaceutical (COLL) - The Globe and Mail
Invesco (NASDAQ: COLL) reports 1.59M Collegium shares (5.0%) - Stock Titan
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2026 Earnings Call Transcript - Insider Monkey
Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a Potential 37% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Collegium Pharmaceutical (COLL) Earnings Growth Far Outpaces Revenue And Tests Cautious Narratives - Sahm
Collegium Pharmaceutical Q1 2026 slides: ADHD growth drives earnings beat - Investing.com Nigeria
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):